Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma
Description
In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including:
- Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCC
- Overview of the Latest Data for the Combination of TACE With Immunotherapy (eg, EMERALD-1 Study of TACE and Durvalumab ± Bevacizumab for Unresectable HCC; and LEAP-012 Study of TACE + Lenvatinib + Pembrolizumab)
- Latest Clinical Data and Updates for Systemic Therapy in Patients With High-Risk Early HCC
Program faculty:
Joseph W. Franses, MD, PhD
Assistant Professor of Medicine
Section of Hematology-Oncology
University of Chicago
Chicago, Illinois
Neehar Parikh, MD, MS
Associate Professor
Li Ka Shing Research Professor of Hepatology
Clinical Director of Hepatology
Medical Director, Liver Tumor Program
Division of Gastroenterology & Hepatology
University of Michigan
Ann Arbor, Michigan
Mark Yarchoan, MD
Associate Professor
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, Maryland
Resources:
To access the resources associated with this podcast discussion, please visit the program page to access a recording from a live webinar and a frequently-asked questions commentary on this topic.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
United States
